Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Background Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment
of inflammatory bowel disease. Aims To determine the efficacy and safety of JAK inhibitors …

Abstract Background & Aims Despite the high burden of hepatitis C virus (HCV) infection
among people who inject drugs (PWID), uptake of interferon‐based therapies has been …

The long‐term effects of direct‐acting antiviral therapies (DAAs) for chronic hepatitis C
(CHC) remain uncertain. The objective of this systematic review and meta‐analysis was to …

There is an urgent need of non-invasive tests (NITs) for monitoring treatment response and
disease progression in chronic liver disease. Liver stiffness (LS) evaluated by transient …

BACKGROUND: The producers of clinical practice guidelines (CPGs) may not disclose
industry funding in their CPGs. We reviewed Canadian national CPGs to examine the …

As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people
who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility …

Background: Avoidable disparities in health outcomes persist in Canada despite substantial
investments in a publicly funded health care system that includes preventive services. Our …

Despite the availability of publicly funded hepatitis C (HCV) treatment in Canada, treatment
gaps persist, particularly among people who inject drugs. We estimate correlates of HCV …

Uterine fibroids (UFs; leiomyoma) are the most common benign neoplastic threat to women
worldwide, exacting an immense personal burden on female health and a monetary …